CRISPR Therapeutics draws attention to CTX310 cardiovascular disease treatment clinical data
CRSP CRISPR Therapeutics AG
$40.37 -4.43%
View chart & analysis → - 1CRISPR Therapeutics reported Phase 1a clinical data in August.
- 2CTX310 showed an average TG reduction of 48% and an average LDL reduction of 53% at the highest dose.
- 3CRISPR Therapeutics is scheduled to report Phase 1b clinical data in early November.
So what's the key point?
CRISPR Therapeutics announced clinical trial results for a cardiovascular disease treatment. The drug showed an effect of lowering blood fat levels by 53%, so the next trial results are also drawing attention.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.